IMUGENE
Developing Cancer Immunotherapies

ASX: IMU

IMUGENE

Investor Presentation

November 2020

DISCLAIMER

1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in **Imugene Limited (Company).**
In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

3. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

4. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

5. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change

6. International offer restrictions - This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which it would be unlawful. In particular, the New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.

INVESTMENT HIGHLIGHTS

- Two novel technologies: B-Cell activating immunotherapies and CF33 oncolytic virotherapy
- B-Cell Technologies: HER-Vaxx Positive Interim Data read out for Phase 2 trial in gastric cancer
- B-Cell Technologies: PD1-Vaxx screening patients in Phase 1 for NSCLC
- CF33 from City of Hope Cancer Centre in Los Angeles
- CF33 has demonstrated single agent & combination activity
- CF33 has prolific and compelling pre-clinical data
- CF33 GMP manufacturing complete for both trials
- Highly experienced CF33 team including CMO from ex OV biotech company and ex-Viralytics clinical development team
- Robust, long life IP portfolio over both technologies
- Significant news flow with multiple near & medium term valuation inflections



TWO NOVEL TECHNOLOGY PLATFORMS



IMUGENE
Developing Cancer Immunotherapies

B-Cell Immunotherapy

HER-Vaxx PHASE 1B: DESIGN & RESULTS

IMUGENE
Developing Cancer Immunotherapies

Trial

- HER2 Gastric or GEJ cancer
- Phase 1b
- Open label
- Dose escalation
- 14 sites in Asia and Eastern Europe

Patients

- Advanced stage IIIb or IV
- 7 HER2+++, 3 HER2++ (FISH positive), 4 HER2++ expressing tumors
- Age 57yo (21 - 79)
- ECOG 1(7) and 0(7)
- 9 Asian, 5 Caucasian
- 5 female, 9 male

Study

- 14 patients in 3 cohorts (10µg (3), 30µg (6) and 50µg (5)
- Dosed on D0, D14, D35
- IMU-131 in combination with chemo: cisplatin and 5FU or capecitabine

Endpoints

- Recommended Phase 2 Dose of IMU-131
- Safety and Toxicity
- Immunogenicity (anti-peptide (P467) and anti-HER-2 antibody titres)

Study Results

- No safety or toxicity issues
- All patients had increased antibody response
- 1 Complete Response
- 5 Partial Response
- 4 Stable Disease
- 1 Progressive Disease
- 50 µg selected as RP2D





HER-Vaxx PHASE 2: RECRUITING

Trial

- Phase 2
- Open label
- Eastern Europe
- India

Patients

- HER-2+++
- HER-2++ FISH/CISH +ve
- Advance or metastatic Gastric Cancer
- Stage IIIb/IV
- 68 patients in two arms

Study

Randomized
HER-Vaxx in combination with standard of care chemotherapy

Or
Standard of care chemo: Cisplatin and 5FU or capecitabine or oxaliplatin

Primary Endpoints

- Overall survival

Secondary Endpoints

- Progression-free survival
- Safety and Tolerability
- Immune response



First patient dosed March 2019

HER-Vaxx PHASE 2: INTERIM ANALYSIS

IMUGENE
Developing Cancer Immunotherapies

Efficacy Outcome Overview

Endpoint	OS ITT * (Primary)	
Treatment	Chemo	Chemo+ HER-Vaxx
All Patients n=27 (at data cut off)	13	14
Events**	8	4
Hazard Ratio (HR)	0.418	
2-sided 80%CI	(0.186,0.942)	
Log-rank Test (1-sided p-value)***	.083+	

*Overall Survival Intent to Treat
**Death
***Pre-specified alpha at 0.10
+ Statistically Significant

HER-Vaxx PHASE 2: INTERIM ANALYSIS

- ✓ Interim analysis showed statistically significant overall survival Hazard Ratio (HR) of 0.418 (80% 2-sided CI: 0.186, 0.942); HER-Vaxx showed a reduced risk of death of 58.2% in the HER-Vaxx plus chemotherapy group as compared to chemotherapy alone.
- ✓ The median overall survival (OS) for patients receiving HER-Vaxx plus chemotherapy was 14.2 months, compared to 8.8 months in patients treated with chemotherapy alone.
- ✓ The Independent Data Monitoring Committee (IDMC) confirms a favourable survival outcome with no added toxicity for HER-Vaxx combined with SOC chemotherapy over chemotherapy alone and advised to reduce the overall number of patients to ~34 and number of required events given the strong signal that it would be considered unethical to enroll 68 as originally planned.
- ✓ The IDMC agreed, that the safety of the study is favorable with no added toxicity for the combination of HER-Vaxx and SOC chemotherapy versus SOC chemotherapy alone.
- ✓ The IDMC agreed that the presented data is strongly encouraging to conclude that the combination of HER-Vaxx and SOC Chemotherapy is safe.
- ✓ The Phase 2 data represent a clinical proof-of-concept signal for HER-Vaxx when added to chemotherapy and indicate that B-cell activating immunotherapy vaccines can induce clinically active antibody responses.

PD1-Vaxx PHASE 1: RECRUITING

Current status

PRE-CLINICAL MILSTONES

CMC manufacturing Complete	Successful pre-clinical FDA de-briefing meeting in Q1, 2019	1st HREC Approval Granted in Australia	Australian Sites Open to Recruitment	FDA/IND Granted	1st Patient Dosed



IMUGENE
Developing Cancer Immunotherapies

CF33: Oncolytic Virus

CHECKvacc: CF33+hNIS+aPD-L1 (“Armed” Virus)

Phase 1 Triple Negative Breast Cancer Study – GMP Manufacturing Complete



- ❑ Disease of need
  - 8-13 month survival for metastatic disease with few treatments
- ❑ Potential target for immunotherapy
  - Expresses PD1, PD-L1
- ❑ Treatment responses to Atezolizumab (JAMA Oncology, 5:74, 2019)
  - 1st line: 24%; 2nd line: 6%
  - Approved by FDA 8-March, 2019
- ❑ Potential for registration in well-designed, randomized P2 study

Indication	TNBC
FDA IND	CHECKvacc: CF33-hNIS-aPDL1
N	Part 1=18-24 ; Part 2=12
Location	Single Center: COH
Admin Route	Intratumoral (IT)

VAXINIA PHASE 1 MAST STUDY (Metastatic Advanced Solid Tumours)

IT Administration
Head & Neck, Advanced Melanoma, TNBC

IV Administration
Head & Neck, Advanced Melanoma, TNBC, NSCLC, Bladder, Gastric, Colorectal, RCC

Part 1: VAXINIA Monotherapy Dose Escalation

Dose Admin IT AND IV

COHORT | 3-6 PATIENTS	COHORT | 3-6 PATIENTS
COHORT | 3-6 PATIENTS	COHORT | 3-6 PATIENTS
COHORT | 3-6 PATIENTS	COHORT | 3-6 PATIENTS
COHORT | 3-6 PATIENTS	COHORT | 3-6 PATIENTS

IDENTIFY MONOTHERAPY

Maximum Feasible Does (MFD)

Based on:

- ✓ Safety
- ✓ Immunogenicity
- ✓ Tumour Response

Part 2: VAXINIA + SOC IO* Combination Dose Escalation

Dose Admin IT AND IV

COHORT | 3-6 PATIENTS	COHORT | 3-6 PATIENTS
COHORT | 3-6 PATIENTS	COHORT | 3-6 PATIENTS
COHORT | 3-6 PATIENTS	COHORT | 3-6 PATIENTS

IDENTIFY COMBINATION

DLT* cleared VAXINIA monotherapy dose combined with IO* in dose escalation cohorts. Select IO* Combination for recommended phase 2 dose (RP2D) based on:

- ✓ Safety
- ✓ Immunogenicity
- ✓ Tumour PD and target Signals

Phase	Phase 1
Indication	IT: Head & Neck, Advanced Melanoma, TNBC IV: Head & Neck, Advanced Melanoma, TNBC, NSCLC, Bladder, Gastric, Colorectal, RCC
Objectives	Safety & MFD
No. of Patients	Approx. 60-120
Site Location	USA

**IO: Immunotherapy*
**DLT: Dose Limiting Toxicity*

MULTIPLE NEAR & MEDIUM TERM VALUE INFLECTION POINTS

PD1-Vaxx

VAXINIA

HER-Vaxx

CHECKvacc



Next 12 months

Leslie Chong
Managing Director & CEO

leslie.chong@imugene.com
+61 458 040 433